Page 233 - EJMO-9-3
P. 233
Eurasian Journal of
Medicine and Oncology FN3K–Nrf2 axis inhibition in breast cancer
61. Khadempar S, Lotfi M, Haghiralsadat F, Saidijam M, H⁺-ATPases as a new strategy against cancer. Cancer Res.
Ghasemi N, Afshar S. Lansoprazole as a potent HDAC2 2007;67(22):10627-10630.
inhibitor for treatment of colorectal cancer: An in-silico doi: 10.1158/0008-5472.CAN-07-1805
analysis and experimental validation. Comput Biol Med.
2023;166:107518. 64. Kao HW, Tsai KW, Lin WC. Synergistic effect of metformin
doi: 10.1016/j.compbiomed.2023.107518 and lansoprazole against gastric cancer through growth
inhibition. Int J Med Sci. 2023;20(6):717-724.
62. Spugnini EP, Buglioni S, Carocci F, et al. High dose
lansoprazole combined with metronomic chemotherapy: doi: 10.7150/ijms.82407
A phase I/II study in companion animals with spontaneously 65. Salo-Ahen OMH, Alanko I, Bhadane R, et al. Molecular
occurring tumors. J Transl Med. 2014;12:225. dynamics simulations in drug discovery and pharmaceutical
doi: 10.1186/s12967-014-0225-y development. Processes. 2021;9(1):71.
63. Fais S, De Milito A, You H, Qin W. Targeting vacuolar doi: 10.3390/pr9010071
Volume 9 Issue 3 (2025) 225 doi: 10.36922/EJMO025150114
